Literature DB >> 19558759

Audit of anticoagulation after embolectomy for acute ischaemia.

T Robinson1, I Hunter, R Wathes, D Keeling, L Hands.   

Abstract

INTRODUCTION: Intravenous unfractionated heparin (UFH) is routinely used in patients after arterial embolectomy. Achieving and maintaining therapeutic levels requires a co-ordinated approach which may be difficult for busy junior doctors and laboratories. There is no current evidence regarding the use of subcutaneous low molecular weight heparin (LMWH) as an alternative. PATIENTS AND METHODS: The study retrospectively examined all patients who had undergone any form of embolectomy during 2006 and 2007 by review of their medical records, an electronic laboratory database, and the patients' drug charts.
RESULTS: Overall, 45 patients were studied. A total of 389 activated partial thromboplastin time (APTT) tests were performed of which 146 (37.6%) were in the therapeutic range (50-90 s), 40.4% were < 50 s and 22.1% were > 90 s. Five patients (11.1%) had further surgical procedures. Significant bleeding occurred in two patients.
CONCLUSIONS: The results indicate that many patients are not appropriately anticoagulated. Whilst a new UFH protocol is being developed by our hospital trust, the authors believe the use of LMWH could provide a more effective and user-friendly alternative to UFH.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19558759      PMCID: PMC2966197          DOI: 10.1308/003588409X432329

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  13 in total

1.  Guidelines on the use and monitoring of heparin.

Authors:  T Baglin; T W Barrowcliffe; A Cohen; M Greaves
Journal:  Br J Haematol       Date:  2006-04       Impact factor: 6.998

Review 2.  Acute pulmonary embolism.

Authors:  Victor F Tapson
Journal:  N Engl J Med       Date:  2008-03-06       Impact factor: 91.245

Review 3.  Low molecular weight heparin.

Authors:  J Hirsh; M N Levine
Journal:  Blood       Date:  1992-01-01       Impact factor: 22.113

Review 4.  Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.

Authors:  A G van Den Belt; M H Prins; A W Lensing; A A Castro; O A Clark; A N Atallah; E Burihan
Journal:  Cochrane Database Syst Rev       Date:  2000

5.  Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.

Authors:  G F Handeland; U Abildgaard; H A Holm; K E Arnesen
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 6.  From unfractionated heparins to low molecular weight heparins.

Authors:  J Hirsh
Journal:  Acta Chir Scand Suppl       Date:  1990

7.  Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Jack Hirsh; Robert Raschke
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

Review 8.  Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  G Patrick Clagett; Michael Sobel; Mark R Jackson; Gregory Y H Lip; Marco Tangelder; Raymond Verhaeghe
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

9.  Differences between low-molecular-weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a metaanalysis.

Authors:  Andrew F Shorr; William L Jackson; John H Sherner; Lisa K Moores
Journal:  Chest       Date:  2007-10-09       Impact factor: 9.410

Review 10.  Cancer and venous thromboembolism: prevention, treatment and survival.

Authors:  Agnes Yuet Ying Lee
Journal:  J Thromb Thrombolysis       Date:  2007-09-29       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.